Results There is some evidence of the effectiveness of medication in treating DBDs , with positive outcomes for lithium and risperidone in particular .
Pharmacotherapy also demonstrated some efficacy in reducing symptoms of aggression .
Medication was relatively well-tolerated , as indicated by equivalent dropout rates in medication and comparison groups .
Rationale Pharmacotherapy is frequently considered in the treatment of  disruptive behavior disorders ( DBDs ) in children and adolescents .
There are , however , no systematic review s of this literature .
Objectives The aim of this work is to determine whether medication is effective in treating pediatric disruptive behavior disorders and related problems of impulse control , as well as to examine differences in the treatment response and tolerability of different medication classes and agents .
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
OBJECTIVE The short-term efficacy and safety of risperidone in the treatment of disruptive behaviors was examined in a well-characterized cohort of children with subaverage intelligence . METHOD In this 6-week , multicenter , double-blind , parallel-group study of 118 children ( aged 5 - 12 years ) with severely disruptive behaviors and subaverage intelligence ( IQ between 36 and 84 , inclusive ) , the subjects received 0.02 - 0.06 mg/kg per day of risperidone oral solution or placebo . The a priori primary efficacy measure was the change in score from baseline to endpoint on the conduct problem subscale of the Nisonger Child Behavior Rating Form . RESULTS The risperidone group showed significantly greater improvement than did the placebo group on the conduct problem subscale of the Nisonger Child Behavior Rating Form from week 1 through endpoint ( change in score of -15.2 and -6.2 , respectively ) . Risperidone was also associated with significantly greater improvement than placebo on all other Nisonger Child Behavior Rating Form subscales at endpoint , as well as on the Aberrant Behavior Checklist subscales for irritability , lethargy/social withdrawal , and hyperactivity ; the Behavior Problems Inventory aggressive/destructive behavior subscale ; a visual analogue scale of the most troublesome symptom ; and the Clinical Global Impression change score . The most common adverse effects reported during risperidone treatment were headache and somnolence . The extrapyramidal symptom profile of risperidone was comparable to that of placebo .  Mean weight increases of 2.2 kg . and 0.9 kg occurred in the risperidone and placebo groups , respectively . CONCLUSIONS Risperidone was effective and well tolerated for the treatment of severely disruptive behaviors in children with subaverage IQ
Results There is some evidence of the effectiveness of medication in treating DBDs , with positive outcomes for lithium and risperidone in particular .
Pharmacotherapy also demonstrated some efficacy in reducing symptoms of aggression .
Medication was relatively well-tolerated , as indicated by equivalent dropout rates in medication and comparison groups .
Rationale Pharmacotherapy is frequently considered in the treatment of  disruptive behavior disorders ( DBDs ) in children and adolescents .
There are , however , no systematic review s of this literature .
Objectives The aim of this work is to determine whether medication is effective in treating pediatric disruptive behavior disorders and related problems of impulse control , as well as to examine differences in the treatment response and tolerability of different medication classes and agents .